Familial Idiopathic Basal Ganglia Calcification: A Father-Son Dyad Demonstrate Heterogeneity of Presentation and Disease Progression.


Journal

Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists
ISSN: 1873-5843
Titre abrégé: Arch Clin Neuropsychol
Pays: United States
ID NLM: 9004255

Informations de publication

Date de publication:
17 Jan 2022
Historique:
received: 20 10 2020
revised: 29 12 2020
accepted: 02 04 2021
pubmed: 25 4 2021
medline: 20 1 2022
entrez: 24 4 2021
Statut: ppublish

Résumé

Familial idiopathic basal ganglia calcification (FIBGC) is a rare, heritable disease characterized by calcium deposition in the basal ganglia and other brain regions. Clinical presentations are diverse, featuring an array of neurologic, psychiatric, and/or cognitive symptoms. This dyad report presents neurogenetic, neuroimaging, neurological, and serial neuropsychological data from a father (S1) and son (S2) with FIBGC. The SLC20A2 genetic mutation c.1828-1831delTCCC was identified for each patient, both of whom evidenced similar patterns of brain calcification mainly in the basal ganglia and cerebellum on neuroimaging. S1's onset was in his late 60s with primary motor abnormalities followed by cognitive decline; S2's younger onset (late 30s) was characterized by predominant psychiatric symptoms and mild cognitive changes. Our unique, detailed longitudinal study revealed that both subjects demonstrated largely stable performance across most neuropsychological domains assessed. The subjects' differences in presentation demonstrate the variable expressivity in FIBGC even with the same pathogenic variant within a single family. Distinct phenotypes may be associated with age of onset even in persons with the same mutation, consistent with past research. Disease progression may feature an initial period of notable change from baseline followed by relative stability, as seen both on imaging and neuropsychological evaluation.

Identifiants

pubmed: 33893476
pii: 6247632
doi: 10.1093/arclin/acab026
pmc: PMC8763112
doi:

Substances chimiques

SLC20A2 protein, human 0
Sodium-Phosphate Cotransporter Proteins, Type III 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

217-225

Subventions

Organisme : CSRD VA
ID : I01 CX001702
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS069719
Pays : United States
Organisme : United States Department of Defense
ID : CX001702
Organisme : NIH HHS
ID : 1R01NS069719
Pays : United States

Informations de copyright

Published by Oxford University Press 2021.

Références

Br J Psychiatry. 1979 Oct;135:360-2
pubmed: 519120
Hum Mutat. 2015 May;36(5):489-95
pubmed: 25726928
Parkinsonism Relat Disord. 2005 Mar;11(2):73-80
pubmed: 15734663
Neurogenetics. 2013 Feb;14(1):11-22
pubmed: 23334463
BMC Neurol. 2016 Sep 08;16:165
pubmed: 27608765
Neurol Sci. 2005 Dec;26(5):367-9
pubmed: 16388376
Nat Genet. 2012 Feb 12;44(3):254-6
pubmed: 22327515
Neuropathology. 2016 Aug;36(4):365-71
pubmed: 26635128
Mov Disord. 2001 Mar;16(2):258-64
pubmed: 11295778
Pol J Radiol. 2017 Sep 15;82:490-493
pubmed: 29662577
Parkinsonism Relat Disord. 2017 Apr;37:1-10
pubmed: 28162874
Am J Hum Genet. 2003 Apr;72(4):839-49
pubmed: 12644968
Neuropediatrics. 1989 Feb;20(1):12-9
pubmed: 2654691
PLoS Comput Biol. 2010 Dec 02;6(12):e1001025
pubmed: 21152010
Biol Psychiatry. 1983 May;18(5):591-601
pubmed: 6860732
N Engl J Med. 1971 Jul 8;285(2):72-7
pubmed: 4326703
Neurol Sci. 2019 Nov;40(11):2251-2263
pubmed: 31267306
Neurology. 1997 Mar;48(3):645-9
pubmed: 9065541
Nat Genet. 2015 Jun;47(6):579-81
pubmed: 25938945
Nat Genet. 2014 Mar;46(3):310-5
pubmed: 24487276
Arch Clin Neuropsychol. 2001 Feb;16(2):183-91
pubmed: 14590186
Mov Disord. 2016 Dec;31(12):1901-1904
pubmed: 27671522
J Mol Neurosci. 2013 Jun;50(2):280-3
pubmed: 23576097
Eur Radiol. 2012 Nov;22(11):2371-81
pubmed: 22688125
J Neurol Neurosurg Psychiatry. 2004 Aug;75(8):1163-5
pubmed: 15258221
Hum Genet. 2002 Jan;110(1):8-14
pubmed: 11810290

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH